Hepatitis Treatment Market: By Disease Type, By Drug Type, By Route of Administration, By Distribution Channel, and Region Forecast 2020-2031
Hepatitis Treatment Market size was valued at US$ 4.44 billion in 2024 and is expected to reach US$ 6.54 billion by 2031, growing at a significant CAGR of 5.7% from 2025-2031. Hepatitis is the disease characterized by the inflammation of the liver. Hepatitis mainly occur due to the viral infections, heavy alcohol intake, consumption of hepatotoxic drugs, blood transfusions and autoimmune diseases among others. Hepatitis is classified as hepatitis A, B, C, D, E in which hepatitis A, B, C mostly occurs in humans. The symptoms associated with hepatitis include poor appetite, whites of eyes, discoloration of skin, vomiting, abdominal pain, and diarrhoea among others. Hepatitis can be prevented by the administration of vaccines in newborn babies.
Increase in the incidence of different types of hepatitis infections, the rise in R&D activities for the development of newer drugs and vaccines, government initiations for the prevention of hepatitis, promising pipeline products for the hepatitis treatment are anticipated to fuel the market over the forecast period. Moreover, the rise in awareness about hepatitis treatment options among key stakeholders, increase in the consumption of alcohol, and high usage of hepatotoxic drugs and other toxins are expected to propel the market over the forecast period. However, stringent regulatory policies for the product approval, lack of vaccines for certain types hepatitis such as hepatitis C, and the high cost of the treatment are expected to hinder the growth of market over the forecast period.
Study Period
2025-2031Base Year
2024CAGR
5.7%Largest Market
North-AmericaFastest Growing Market
Europe
hepatitis treatment market is driven by rising in the prevalence of various types of hepatitis infections. According to WHO in 2015, approximately 257 Mn hepatitis B, 71 Mn hepatitis C cases, and approximately 15 Mn hepatitis D cases observed around the globe. Majority of the local and international market players are actively seeking to develop newer drugs and vaccines for the treatment of hepatitis infection. Moreover, strong product pipeline for hepatitis treatment expected to upsurge the market revenue over the forecast timeframe. Furthermore, acquisitions and mergers, product approvals, and product launchings are the strategies adopted by the market players for dominating the market.
Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America market is poised to grow due to increase in the prevalence of hepatitis infection, the rise in R&D activities for the innovation of new drugs, an increase in healthcare expenditure in the region. Europe market expected to exhibit lucrative growth owing to rise in prevalence of hepatitis due to change in lifestyle, increase in awareness about the hepatitis treatment, and adoption of newer drugs and vaccines are propelling the market.
Asia Pacific hepatitis treatment market is growing due to increase in the geriatric population in India, China, and Japan, the rise in healthcare expenditure, and launching of generic drugs into the market. Latin America market is driven by an increase in hepatitis C infection, launching of newer products into the market, and increase in the awareness about hepatitis treatment. Middle East and Africa market growth is attributed to economic growth, increase in the prevalence of hepatitis infection in African countries, and expansion of businesses by market players in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 4.44 billion |
|
Market Size in 2031 |
US$ 6.54 billion |
|
Market CAGR |
5.7% |
|
By Disease Type |
|
|
By Drug Type |
|
|
By Route Administration |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The hepatitis treatment market size was valued at US$ 4.44 billion in 2024 and is projected to grow at a significant CAGR of 5.7% from 2025-2031.
Hoffmann- La Roche Ltd, Gilead Sciences, Novartis AG, Bristol-Myers Squibb, GlaxoSmithKline, plc.
Europe is the fastest-growing region for market.
| 1.Executive Summary |
| 2.Global Hepatitis Treatment Market Introduction |
| 2.1.Global Hepatitis Treatment Market - Taxonomy |
| 2.2.Global Hepatitis Treatment Market - Definitions |
| 2.2.1.Disease Type |
| 2.2.2.Drug Type |
| 2.2.3.Route of Administration |
| 2.2.4.Distribution Channel |
| 2.2.5.Region |
| 3.Global Hepatitis Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Hepatitis Treatment Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Hepatitis Treatment Market By Disease Type , 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Hepatitis A |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Hepatitis B |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Hepatitis C |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Hepatitis D |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Hepatitis E |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6.Global Hepatitis Treatment Market By Drug Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Vaccines |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Anti-Viral Drugs |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Interferons |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Hepatitis Treatment Market By Route of Administration, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Oral |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Parenteral |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8.Global Hepatitis Treatment Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. Hospital Pharmacies |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacies |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacies |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9.Global Hepatitis Treatment Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Hepatitis Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Disease Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Hepatitis A |
| 10.1.2.Hepatitis B |
| 10.1.3.Hepatitis C |
| 10.1.4.Hepatitis D |
| 10.1.5.Hepatitis E |
| 10.1.6.Others |
| 10.2. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Vaccines |
| 10.2.2.Anti-Viral Drugs |
| 10.2.3.Interferons |
| 10.2.4.Others |
| 10.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Oral |
| 10.3.2.Parenteral |
| 10.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospital Pharmacies |
| 10.4.2.Retail Pharmacies |
| 10.4.3.Online Pharmacies |
| 10.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Hepatitis Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Hepatitis A |
| 11.1.2.Hepatitis B |
| 11.1.3.Hepatitis C |
| 11.1.4.Hepatitis D |
| 11.1.5.Hepatitis E |
| 11.1.6.Others |
| 11.2. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Vaccines |
| 11.2.2.Anti-Viral Drugs |
| 11.2.3.Interferons |
| 11.2.4.Others |
| 11.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Oral |
| 11.3.2.Parenteral |
| 11.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospital Pharmacies |
| 11.4.2.Retail Pharmacies |
| 11.4.3.Online Pharmacies |
| 11.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 11.5.7. |
| 12.Asia Pacific (APAC) Hepatitis Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Hepatitis A |
| 12.1.2.Hepatitis B |
| 12.1.3.Hepatitis C |
| 12.1.4.Hepatitis D |
| 12.1.5.Hepatitis E |
| 12.1.6.Others |
| 12.2. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Vaccines |
| 12.2.2.Anti-Viral Drugs |
| 12.2.3.Interferons |
| 12.2.4.Others |
| 12.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Oral |
| 12.3.2.Parenteral |
| 12.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospital Pharmacies |
| 12.4.2.Retail Pharmacies |
| 12.4.3.Online Pharmacies |
| 12.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Hepatitis Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Hepatitis A |
| 13.1.2.Hepatitis B |
| 13.1.3.Hepatitis C |
| 13.1.4.Hepatitis D |
| 13.1.5.Hepatitis E |
| 13.1.6.Others |
| 13.2. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Vaccines |
| 13.2.2.Anti-Viral Drugs |
| 13.2.3.Interferons |
| 13.2.4.Others |
| 13.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Oral |
| 13.3.2.Parenteral |
| 13.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospital Pharmacies |
| 13.4.2.Retail Pharmacies |
| 13.4.3.Online Pharmacies |
| 13.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Hepatitis Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 14.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Hepatitis A |
| 14.1.2.Hepatitis B |
| 14.1.3.Hepatitis C |
| 14.1.4.Hepatitis D |
| 14.1.5.Hepatitis E |
| 14.1.6.Others |
| 14.2. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Vaccines |
| 14.2.2.Anti-Viral Drugs |
| 14.2.3.Interferons |
| 14.2.4.Others |
| 14.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Oral |
| 14.3.2.Parenteral |
| 14.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospital Pharmacies |
| 14.4.2.Retail Pharmacies |
| 14.4.3.Online Pharmacies |
| 14.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Hoffmann- La Roche Ltd. (Switzerland) |
| 15.2.2.Gilead Sciences (U.S.) |
| 15.2.3.Novartis AG (Switzerland) |
| 15.2.4.Bristol-Myers Squibb (U.S) |
| 15.2.5.GlaxoSmithKline, plc. |
| 15.2.7.Merck and Co, Inc. (U.S) |
| 15.2.8.Johnson & Johnson Services, Inc. (U.S.) |
| 15.2.9.AbbVie Inc. (U.S.) |
| 15.2.10.Novira Therapeutics Inc. (U.S.) |
| 15.2.11.Eiger Biopharmaceuticals (U.S.) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
